OmniAb Inc. Total Assets
OmniAb Inc. total assets. Based on the latest financial reports, OmniAb Inc. (OABI) holds total assets worth $290.26 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see OABI market cap for the company's overall valuation and market capitalisation.
Total Assets of OmniAb Inc. (2019–2025)
Total assets of OmniAb Inc. from 2019 to 2025. This chart illustrates how OmniAb Inc.'s total assets have evolved over time, based on quarterly financial data. See OABI stock price for real-time trading data and today's change.
OmniAb Inc. - Asset Composition Analysis
OmniAb Inc. Total Assets Breakdown (December 2025)
OmniAb Inc. total assets breakdown as of December 2025. OmniAb Inc.'s total assets of $290.26 Million consist of 21.7% current assets and 78.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.5% |
| Accounts Receivable | $7.39 Million | 2.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $125.15 Million | 41.6% |
| Goodwill | $83.98 Million | 27.9% |
Asset Composition Trend (2019–2025)
This chart illustrates how OmniAb Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore OABI working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OmniAb Inc.'s current assets represent 21.7% of total assets in 2025, an increase from 3.0% in 2019.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2025, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 68.0% of total assets, a decrease from 94.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 41.6% of total assets.
OmniAb Inc. Competitors by Total Assets
Key competitors of OmniAb Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
OmniAb Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.80 | 3.77 | 0.40 |
| Quick Ratio | 4.72 | 3.77 | 0.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $52.26 Million | $34.98 Million | $-8.64 Million |
OmniAb Inc. - Advanced Valuation Insights
This section examines the relationship between OmniAb Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.25 |
| Latest Market Cap to Assets Ratio | 1.91 |
| Asset Growth Rate (YoY) | -7.6% |
| Total Assets | $300.91 Million |
| Market Capitalization | $574.29 Million USD |
Valuation Analysis
Above Book Valuation: The market values OmniAb Inc.'s assets above their book value (1.91x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: OmniAb Inc.'s assets decreased by 7.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OmniAb Inc. (2019–2025)
The table below shows the annual total assets of OmniAb Inc. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $300.91 Million | -7.57% |
| 2024-12-31 | $325.56 Million | -13.24% |
| 2023-12-31 | $375.23 Million | -10.92% |
| 2022-12-31 | $421.21 Million | +38.34% |
| 2021-12-31 | $304.46 Million | +3.08% |
| 2020-12-31 | $295.38 Million | +12.60% |
| 2019-12-31 | $262.32 Million | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more